BRPI0719529A2 - Método para produzir uma preparação sólida, e, preparação sólida. - Google Patents

Método para produzir uma preparação sólida, e, preparação sólida.

Info

Publication number
BRPI0719529A2
BRPI0719529A2 BRPI0719529-0A2A BRPI0719529A BRPI0719529A2 BR PI0719529 A2 BRPI0719529 A2 BR PI0719529A2 BR PI0719529 A BRPI0719529 A BR PI0719529A BR PI0719529 A2 BRPI0719529 A2 BR PI0719529A2
Authority
BR
Brazil
Prior art keywords
solid preparation
producing
producing solid
preparation
solid
Prior art date
Application number
BRPI0719529-0A2A
Other languages
English (en)
Inventor
Tomoyuki Watanabe
Original Assignee
Daiichi Sankyo Company Ltd E Ube Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company Ltd E Ube Ind Ltd filed Critical Daiichi Sankyo Company Ltd E Ube Ind Ltd
Publication of BRPI0719529A2 publication Critical patent/BRPI0719529A2/pt
Publication of BRPI0719529B1 publication Critical patent/BRPI0719529B1/pt
Publication of BRPI0719529B8 publication Critical patent/BRPI0719529B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0719529A 2006-12-07 2007-12-06 método para produzir uma preparação sólida BRPI0719529B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006330373 2006-12-07
JP2006-330373 2006-12-07
PCT/JP2007/073549 WO2008072533A1 (ja) 2006-12-07 2007-12-06 固形製剤の製造方法

Publications (3)

Publication Number Publication Date
BRPI0719529A2 true BRPI0719529A2 (pt) 2014-01-21
BRPI0719529B1 BRPI0719529B1 (pt) 2020-10-06
BRPI0719529B8 BRPI0719529B8 (pt) 2021-05-25

Family

ID=39511553

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719529A BRPI0719529B8 (pt) 2006-12-07 2007-12-06 método para produzir uma preparação sólida

Country Status (9)

Country Link
US (3) US20110201814A1 (pt)
EP (1) EP2100608A4 (pt)
JP (1) JP5433235B2 (pt)
KR (1) KR101503083B1 (pt)
CN (1) CN101594864B (pt)
BR (1) BRPI0719529B8 (pt)
CA (1) CA2672157C (pt)
TW (1) TWI405591B (pt)
WO (1) WO2008072533A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI482641B (zh) 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
EP2360159A1 (de) 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon
CN102268012B (zh) * 2011-08-24 2014-04-09 天津药物研究院 噻唑衍生物、其制备方法和用途
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
WO2018073437A1 (en) 2016-10-21 2018-04-26 Laboratorios Lesvi, Sl Pharmaceutical formulations of prasugrel and processes for the preparation thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211958A (en) * 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
GB9414045D0 (en) * 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
JPH09208458A (ja) * 1996-02-02 1997-08-12 Ss Pharmaceut Co Ltd 不快な味がマスキングされた製剤
TW473393B (en) * 1996-02-29 2002-01-21 Fujisawa Pharmaceutical Co Beta-lactam antibiotic-containing tablet and production thereof
JPH10310586A (ja) * 1996-06-26 1998-11-24 Sankyo Co Ltd ヒドロピリジン類の新規医薬用途
PT1586314E (pt) * 1996-11-15 2011-07-01 Ajinomoto Kk Composição de comprimidos de nateglinida
US6627117B2 (en) * 1998-06-09 2003-09-30 Geotech Chemical Company, Llc Method for applying a coating that acts as an electrolytic barrier and a cathodic corrosion prevention system
DE60110666T2 (de) * 2000-03-17 2006-02-02 Shin-Etsu Chemical Co., Ltd. Feste Zubereitung enthaltend niedersubstituierte Hydroxypropylcellulose und Herstellungsverfahren
CA2342121C (fr) * 2000-03-29 2010-05-25 Roquette Freres Mannitol pulverulent et son procede de preparation
KR20080021152A (ko) * 2000-07-06 2008-03-06 다이이찌 산쿄 가부시키가이샤 히드로피리딘 유도체 산부가염
JP4001199B2 (ja) 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
CZ297570B6 (cs) * 2000-12-25 2007-02-07 Sankyo Company, Limited Farmaceutický prípravek obsahující 2-acetoxypyridinový derivát a aspirin, které spolu pusobí v synergickém úcinku, kit jej obsahující a pouzití
KR100908418B1 (ko) * 2001-06-20 2009-07-21 액티버스 파마 컴퍼니 리미티드 퀴놀리논 유도체 의약 조성물 및 그의 제조 방법
JP3939601B2 (ja) * 2001-06-20 2007-07-04 株式会社アクティバスファーマ キノリノン誘導体医薬組成物及びその製造方法
JP4029974B2 (ja) 2001-12-21 2008-01-09 第一三共株式会社 ヒドロピリジン誘導体酸付加塩を含有する医薬
US20050192245A1 (en) * 2002-07-18 2005-09-01 Sankyo Company, Limited Medicinal composition for treating arteriosclerosis
JP2004051639A (ja) 2002-07-18 2004-02-19 Sankyo Co Ltd 動脈硬化症治療のための医薬組成物
RU2005104432A (ru) * 2002-07-18 2005-08-10 Санкио Компани, Лимитед (Jp) Лекарственная композиция для лечения артериосклероза
WO2004091600A1 (ja) * 2003-04-16 2004-10-28 Kyorin Pharmaceutical Co., Ltd. 経口固形製剤
EP1660183A2 (en) * 2003-05-05 2006-05-31 Eli Lilly and Company Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4)
US20060280794A1 (en) * 2003-06-06 2006-12-14 Naoru Hamaguchi Solid pharmaceutical preparation
KR20080083071A (ko) * 2003-08-08 2008-09-12 아지노모토 가부시키가이샤 나테글리니드 함유 제제
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor

Also Published As

Publication number Publication date
CN101594864B (zh) 2012-04-18
CA2672157C (en) 2016-07-26
KR20090090322A (ko) 2009-08-25
BRPI0719529B1 (pt) 2020-10-06
US20130249140A1 (en) 2013-09-26
US20120077980A1 (en) 2012-03-29
EP2100608A1 (en) 2009-09-16
BRPI0719529B8 (pt) 2021-05-25
CN101594864A (zh) 2009-12-02
CA2672157A1 (en) 2008-06-19
TW200833371A (en) 2008-08-16
KR101503083B1 (ko) 2015-03-16
TWI405591B (zh) 2013-08-21
JPWO2008072533A1 (ja) 2010-03-25
JP5433235B2 (ja) 2014-03-05
EP2100608A4 (en) 2009-12-09
US20110201814A1 (en) 2011-08-18
WO2008072533A1 (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
BRPI0716439A2 (pt) formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas.
BRPI0811750A2 (pt) Método para produzir um inversor de enriquecimento-empobrecimento, e, inversor
BRPI0720677A2 (pt) Aparelho e método para produzir carvão.
BRPI0812847A2 (pt) Uretano acrilado, composição, e, método para reticular pelo menos parcialmente a composição
BRPI0719272A2 (pt) Composição de enzima, e, método para preparar uma composição de enzima.
BRPI0717041A2 (pt) produto alimentÍcio gaseificado, e, mÉtodo para preparar o mesmo
BRPI0916689A2 (pt) composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
NL2001649A1 (nl) Non-bolt joint structure and method for producing non-bolt joint structure.
BRPI0814299A2 (pt) Preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI0819127A2 (pt) Método para cimentar.
BRPI0809573A8 (pt) composição, e, método
BRPI0807756A2 (pt) Método para produzir um l-aminoácido.
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
BRPI0814466A2 (pt) Método.
BR112012002608A2 (pt) composição lubrificante, e, método para melhorar o desempenho de uma composição lubrificante.
BRPI1008021A2 (pt) Método para fabricação de 2,6-dioxabiciclo-(3.3.0)-octano-4,8-diona
BRPI0908092A2 (pt) Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante
BRPI0817727A2 (pt) composição de graxa lubrificante, e, método para preparar uma composição de graxa
BRPI0720703A2 (pt) Método para a preparação de uma peneira molecular, e, peneira molecular de poros pequenos
BRPI0923801A2 (pt) Métodos para produzir um éster, e para produzir amidas.
BRPI0815796A2 (pt) Compósito elastomérico e método para produzi-lo.
BRPI0918642A2 (pt) coque e método para fabricação do mesmo.
MX325514B (es) Metodo para elaborar cetales y acetales.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: DAIICHI SANKYO COMPANY, LIMITED (JP) ; UBE CORPORATION (JP)